BR112013018298A2 - compostos para a redução da produção de beta-amiloides - Google Patents

compostos para a redução da produção de beta-amiloides

Info

Publication number
BR112013018298A2
BR112013018298A2 BR112013018298A BR112013018298A BR112013018298A2 BR 112013018298 A2 BR112013018298 A2 BR 112013018298A2 BR 112013018298 A BR112013018298 A BR 112013018298A BR 112013018298 A BR112013018298 A BR 112013018298A BR 112013018298 A2 BR112013018298 A2 BR 112013018298A2
Authority
BR
Brazil
Prior art keywords
compounds
reducing beta
amyloid
amyloid production
production
Prior art date
Application number
BR112013018298A
Other languages
English (en)
Inventor
Dmitry S Zuev
Jason M Guernon
Jianliang Shi
John E Macor
Kenneth M Boy
Li Xu
Lorin A Thompson Iii
Richard E Olson
Yong-Jin Wu
Yunhui Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112013018298A2 publication Critical patent/BR112013018298A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

compostos para a redução da produção de beta-amiloides a presente invenção refere-se a uma série de compostos da fórmula (i) que modulam a produção de peptídios <225>-amiloides (<225>-ap) e são úteis no tratamento do mal de alzheimer e de outras condições afetas pela produção de peptídeos <225>-amiloides (<225>-ap).
BR112013018298A 2011-01-28 2012-01-26 compostos para a redução da produção de beta-amiloides BR112013018298A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437279P 2011-01-28 2011-01-28
PCT/US2012/022665 WO2012103297A1 (en) 2011-01-28 2012-01-26 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (1)

Publication Number Publication Date
BR112013018298A2 true BR112013018298A2 (pt) 2016-11-16

Family

ID=45688981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018298A BR112013018298A2 (pt) 2011-01-28 2012-01-26 compostos para a redução da produção de beta-amiloides

Country Status (15)

Country Link
US (1) US8710061B2 (pt)
EP (1) EP2668168B1 (pt)
JP (1) JP5908499B2 (pt)
KR (1) KR20140014152A (pt)
CN (1) CN103328451B (pt)
AR (1) AR084944A1 (pt)
AU (1) AU2012211301B2 (pt)
BR (1) BR112013018298A2 (pt)
CA (1) CA2825906A1 (pt)
EA (1) EA201391097A1 (pt)
IL (1) IL226677A (pt)
MX (1) MX2013008699A (pt)
SG (1) SG191840A1 (pt)
TW (1) TW201309655A (pt)
WO (1) WO2012103297A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102227271B1 (ko) 2013-04-15 2021-03-12 에프엠씨 코포레이션 살진균성 아미드
WO2016080516A1 (ja) * 2014-11-21 2016-05-26 味の素株式会社 Ｄｒｐ１重合阻害剤
EP3778605A3 (en) * 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN105017046A (zh) * 2015-07-15 2015-11-04 上海博康精细化工有限公司 一种4-环丙胺基丁酸乙酯的制备方法
AU2016295594B2 (en) * 2015-07-21 2020-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
CN111315739B (zh) * 2017-11-27 2023-12-05 豪夫迈·罗氏有限公司 嘧啶衍生物
EP3919484B1 (en) * 2019-01-29 2023-05-24 Shandong Xuanzhu Pharma Co., Ltd. Hexone glucokinase inhibitor and use thereof
CN112028839B (zh) * 2020-09-30 2022-04-12 中国海洋大学 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698627A1 (en) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20100311965A1 (en) * 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) * 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production

Also Published As

Publication number Publication date
EA201391097A1 (ru) 2013-11-29
AU2012211301B2 (en) 2016-02-25
KR20140014152A (ko) 2014-02-05
EP2668168B1 (en) 2017-03-01
JP2014503590A (ja) 2014-02-13
AU2012211301A1 (en) 2013-09-19
SG191840A1 (en) 2013-08-30
EP2668168A1 (en) 2013-12-04
IL226677A (en) 2014-11-30
AR084944A1 (es) 2013-07-10
US20130030011A1 (en) 2013-01-31
JP5908499B2 (ja) 2016-04-26
CN103328451B (zh) 2015-06-10
CA2825906A1 (en) 2012-08-02
CN103328451A (zh) 2013-09-25
MX2013008699A (es) 2013-08-21
TW201309655A (zh) 2013-03-01
US8710061B2 (en) 2014-04-29
WO2012103297A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
CY1120805T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
BR112015014253A2 (pt) produtos de higiene bucal que compreendem um complexo de haleto de aminoácido e zinco tetrabásico
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
MX369388B (es) Moduladores heterociclicos de sintesis lipidica.
MX2012007981A (es) Derivados de fumarato de acido graso y sus usos.
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
BR112013020513A2 (pt) adoçante stevia altamente solúvel
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
BR112014008401A2 (pt) processo para a preparação de metoxi melonal
SG10201900541QA (en) Derivatives of xanthone compounds
GEP20146183B (en) Process for preparation of l-arginine salt of perindopril
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
BR112014009760A8 (pt) análogos de ácido siálico
BR112013029416A2 (pt) derivados de indol substituídos para o tratamento de distúrbios imunológicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.